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BACKGROUND: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) can cause resistance to the alkylating
drug temozolomide (TMZ). The purpose of this study was to determine the relationship between the MGMT status, determined by
means of several techniques and methods, and the cytotoxic response to TMZ in 11 glioblastoma multiforme (GBM) cell lines and 5
human tumour cell lines of other origins.
METHODS: Cell survival was analysed by clonogenic assay. The MGMT protein levels were assessed by western blot analysis. The
MGMT promoter methylation levels were determined using methylation-specific multiplex ligation-dependent probe amplification
(MS-MLPA) and quantitative real-time methylation-specific PCR (qMSP). On the basis of the results of these techniques, six GBM cell
lines were selected and subjected to bisulphite sequencing.
RESULTS: The MGMT protein was detected in all TMZ-resistant cell lines, whereas no MGMT protein could be detected in cell lines
that were TMZ sensitive. The MS-MLPA results were able to predict TMZ sensitivity in 9 out of 16 cell lines (56%). The qMSP results
matched well with TMZ sensitivity in 11 out of 12 (92%) glioma cell lines. In addition, methylation as detected by bisulphite
sequencing seemed to be predictive of TMZ sensitivity in all six cell lines analysed (100%).
CONCLUSION: The MGMT protein expression more than MGMT promoter methylation status predicts the response to TMZ in human
tumour cell lines.
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Glioblastoma multiforme (GBM) is the most frequent and most
malignant primary brain tumour. Despite surgery, adjuvant radio-
therapy and chemotherapy, GBM often recur. Addition of temozo-
lomide (TMZ) to fractionated radiotherapy for newly diagnosed
GBM improved the median survival from 12 to 14 months and the
5-year overall survival from 1.9 to 9.8% (Stupp et al, 2005, 2009).
TMZ, an alkylating cytostatic drug, acts through methylation of
the O6 position of guanine; the resulting DNA lesions are considered
to be responsible for the cytotoxic effect (Stevens et al, 1987; Tisdale,
1987). Presence of the DNA repair protein O6-methylguanine-DNA
methyltransferase (MGMT) can cause resistance to alkylating
agents, including TMZ, by removing the methyl group from the
O6 position of guanine (Brennand and Margison, 1986).
Both transcriptional silencing of theMGMT gene by methylation
of the CpG dinucleotides (CpGs) in the promoter region as well as
absence of MGMT protein have been associated with a good
clinical response to alkylating agents in general and in particular to
TMZ in patients with an anaplastic astrocytoma or GBM (Esteller
et al, 2000; Hegi et al, 2005; Chinot et al, 2007; Nagane et al, 2007;
Sadones et al, 2009). However, the few studies comparing different
approaches to determination of the MGMT status all show a lack of
correlation between MGMT protein expression and MGMT
promoter methylation (Brell et al, 2005; Jeuken et al, 2007;
Preusser et al, 2008; Rodriguez et al, 2008; Yachi et al, 2008).
Prediction of the TMZ sensitivity in clinical tumour samples
would greatly improve the patients’ treatment. However, to have
clinical value, such an assay needs to be accurate, reliable and
relatively convenient.
The purpose of this study was to determine whether the in vitro
cytotoxic response to TMZ, evaluated by clonogenic assay, is
associated with either MGMT expression and/or promoter methyla-
tion. In a panel of 16 human cancer cell lines, mostly derived from
human GBM, MGMT protein expression was measured by western
blot analysis. The MGMT promoter methylation levels were assayed
by methylation-specific multiplex ligation-dependent probe amplifi-
cation (MS-MLPA), methylation-specific PCR (MSP), quantitative
real-time MSP (qMSP) and bisulphite sequencing.
MATERIALS AND METHODS
Cell lines
Sixteen cell lines were cultured at 371C in medium containing
foetal calf serum (FCS), 2mmol l – 1 L-glutamine, 100 IUml–1Revised 5 May 2010; accepted 6 May 2010; published online 1 June 2010
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penicillin and 100 IUml–1 streptomycin (all from Invitrogen,
Groningen, The Netherlands). The PC-3 cell line (prostate
adenocarcinoma) was cultured in RPMI-1640 medium with 10%
FCS. A-431 (epidermoid carcinoma), Gli-6 (GBM; Fehlauer et al,
2000) and HT-29 (colorectal adenocarcinoma) were cultured in
Dulbecco’s modified Eagle’s medium (D-MEM) with 10% FCS. In
D-MEM with 20% FCS, AMC 3046, AMC 3344, VU-28, VU-98,
VU-109, VU-110 and VU-122 were cultured (all GBM; van Nifterik
et al, 2007). The above-mentioned 11 cell lines were cultured in a
7% CO2-humidified atmosphere. Furthermore, five cell lines were
cultured in a humidified atmosphere without CO2 using Leibovitch
L15 medium with 10% FCS: D384 (astrocytoma grade III;
Balmforth et al, 1986), Hs 683 (GBM), SW 1573 (alveolar cell
carcinoma), T98G (GBM) and U251 (GBM). Experiments were
performed on cells from the same batch with the same cell passage
number, except for western blot analysis of the T98 cell line.
Clonogenic cell survival after TMZ treatment
The experiment was performed as described earlier (van Nifterik
et al, 2007). After 24 h exposure of TMZ, the medium was replaced
either with fresh conditioned medium (AMC 3046, VU-109 and
VU-110) or fresh normal medium (all other cell lines) for the
remaining part of the clonogenic assay. Average plating efficiencies
(for the untreated cell lines) were 50% (A-431), 17% (AMC 3046),
12% (AMC 3344), 62% (D384), 49% (Gli-6), 30% (HS683), 67%
(HT-29), 40% (PC-3), 56% (SW1573), 42% (T98), 33% (U251), 4%
(VU-28), 7% (VU-98), 16% (VU-109), 6% (VU-110) and 36%
(VU-122). The results for AMC 3046, AMC 3344, VU-28, VU-98,
VU-109, VU-110 and VU-122 have already been published (van
Nifterik et al, 2007).
MGMT protein expression by western blot analysis
The analysis was performed as described earlier (van Nifterik et al,
2007) except that for the cell line HT-29, because of an abundance
of targeted protein, 25 mg instead of 50 mg of protein sample were
used. For western blot analysis of AMC 3344 also 100mg of protein
were used. Colon carcinomas, in this study HT-29, are a positive
control for the MGMT protein. Membranes were checked for
successful protein transfer and loading control by incubation of
the membranes for 1min in ponceau S.
Methylation analysis
MGMT promoter methylation analysis by MS-MLPA The
MS-MLPA is a semi-quantitative method for methylation
profiling using a methylation-sensitive restriction enzyme (Nygren
et al, 2005). The SALSA MS-MLPA kit ME011 (MRC-Holland,
Amsterdam, The Netherlands) was used to determine the
promoter methylation status of the MGMT gene. The kit contains
three different probes that specifically target three CpGs within
the MGMT promoter region (Figure 1): MS-MLPA A, MS-MLPA B
and MS-MLPA C, located from 459 to 458, 313 to 312
and 72 to 73 base pairs (bp) from the transcription start site
(TSS), respectively. The MS-MLPA was performed with
approximately 100 ng DNA according to the protocol provided
by the manufacturer. The amplified PCR products were separated
by electrophoresis on an ABI PRISM 3730 fragment analyser
(Applied Biosystems, Foster City, CA, USA) and analysed
using Genemarker analysis software version 1.5 (SoftGenetics,
LLC, State College, PA, USA). Data are presented in percentage
of methylation (mean of two independent experiments)
and classified as low (0–40%), intermediate (40–75%) and high
(75–100%).
MGMT promoter methylation analysis by MSP Methylation-
specific PCR is based on the amplification of bisulphite-converted
DNA, which can distinguish specifically between methylated and
unmethylated DNA with a high sensitivity (Herman et al, 1996).
Genomic DNA isolated from cell lines was subjected to bisulphite
modification using the EZ DNA Methylation kit (Zymo Research,
Orange, CA, USA) according to the protocol provided by the
manufacturer. Sodium bisulphite converts unmethylated cytosines
to uracils, whereas methylated cytosines are unaffected. Two MSPs
were performed targeting two CpG-rich regions within the MGMT
promoter using primer sets listed in Table 1. The forward primers
of MSP1 (3 CpGs) and MSP 2 (5 CpGs; Esteller et al, 1999) each
contain a CpG that is also detectable by MS-MLPA probes A and C,
respectively (Figure 1). The housekeeping gene b-actin (ACTB)
was used as internal control of both bisulphite conversion DNA
quality (Harden et al, 2003). In the reaction, 50 ng bisulphite-
treated genomic DNA was amplified with FastStart Taq PCR buffer
(Roche Diagnostics, Almere, The Netherlands) with 1.5mM MgCl2,
0.5 mM primers, each dNTP at 200 mM, and 1.25U of FastStart Taq
DNApolymerase in a total volume of 25 ml. Amplification reaction
was carried out in a GeneAmp PCR system 9700 using the
following conditions: 951C for 4min, followed by 38 (MSP1 and
MSP2) or 40 (ACTB) cycles of 951C for 30 s, 611C (MSP1) or 591C
(MSP2) or 601C (ACTB) for 30 s and 721C for 45 s, with a final
extension of 721C for 4min. The cervical cancer cell line CaSki
(which is methylated for the MGMT gene) was used as positive
control, whereas unmethylated (primary keratinocytes), unmodi-
fied DNA and H2O were included as negative controls. The PCR
products were detected by UV light on a 2% agarose gel stained
with ethidium bromide. A 100-bp DNA ladder (Amersham
Biosciences, Buckinghamshire, UK) was used as a marker. All
MSP reactions were performed in duplicate.
MGMT promoter methylation analysis by qMSP The qMSP is
based on the same principle as MSP, but uses a probe, in this case a
Taqman probe, for real-time quantification of amplification
products (Vlassenbroeck et al, 2008). The primers and probe
included in the qMSP are listed in Table 1 (see also Figure 1); the
same primer set of MSP2 (Esteller et al, 1999) was used for
the quantitative format. For the amplification reaction, 2.5 ml
TSS
200100–100–200–300–400–500 0
MS-MLPA 
probe A
MS-MLPA 
probe B
MS-MLPA 
probe C
MSP1/qMSP amplicon
qMSP probe
MSP2 amplicon
Bisulphite sequencing
Figure 1 Locations on the MGMT promoter for the amplicons of the primer sets for MSP1/qMSP, MSP2, and bisulphite sequencing, and locations for
probe qMSP and MS-MLPA probes A, B and C. TSS¼ transcription start site.
MGMT status predicts TMZ sensitivity
KA van Nifterik et al
30
British Journal of Cancer (2010) 103(1), 29 – 35 & 2010 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
bisulphite-treated DNA was added to 9.5 ml amplification mix
containing 1 Quantitect Probe mix (Qiagen, Venlo, The
Netherlands), 0.8mM of each primer and 0.208 mM of the 50JOE/
30BHQ1-labelled probe. Amplification and real-time measurement
were performed in the 7500Fast ABI system under the following
conditions: 15min at 951C followed by 45 cycles of 30 s at 951C and
1min at 601C. The reaction included multiple water blanks, as
negative control, and serial dilutions of the CaSki cell line. As
reference, the gene ACTB was used to control bisulphite
conversion and total input DNA (Harden et al, 2003). Promoter
methylation levels were calculated with the formula [(target gene/
ACTB) 1000]. The cutoff value for discrimination between
methylation levels was 4200¼methylated, and o200¼
unmethylated or low methylated. All samples were tested in
duplicate. When discrepant results were obtained, the samples
were analysed in quadruplicate and scored positive if at least two
reactions were positive.
MGMT promoter methylation analysis by bisulphite sequencing
Bisulphite sequencing was performed in an area of the MGMT
promoter not tested before with MS-MLPA, MSP or qMSP
(Figure 1). For bisulphite-sequencing analysis, bisulphite-treated
genomic DNA of the GBM cell lines AMC 3344, VU-28, VU110, Hs
683, U251 and the astrocytoma grade III cell line D384 (selected on
the basis of the results of western blot and MS-MLPA) was
amplified using primers listed in Table 1. The PCR mixtures
contained 50 ng bisulphite-treated genomic DNA, FastStart Taq
PCR buffer (Roche Diagnostics) with 1.5mM MgCl2, 0.5 mM
primers, each dNTP at 200mM, and 1.25U of FastStart Taq
DNApolymerase in a total volume of 25 ml. Amplification reaction
was carried out in a GeneAmp PCR system 9700 using the
following conditions: 951C for 4min, followed by 40 cycles of 951C
for 30 s, 551C for 30 s and 721C for 45 s, with a final extension of
721C for 4min. Amplified PCR products were purified using the
ExoI and SAP (USB Europe GmbH, Staufen, Germany) according
to the manufacturer’s specifications, and were sequenced directly
using the forward or the reverse primer and the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). After
each sample was purified with the BigDye XTerminator Purifica-
tion kit, each sequencing product was subsequently analysed by
electrophoresis in the 3130 Genetic Analyser (Applied Biosystems).
Sixty-two CpGs were analysed, that is every CpG located between
329 and þ 91 bp from the TSS.
RESULTS
Clonogenic cell survival after TMZ treatment
A panel of 16 human tumour cell lines, including 12 gliomas
(11 GBM and 1 astrocytoma grade III) and 4 other carcinoma cell
lines, was tested for their response to 24 h treatment with different
concentrations of TMZ. Cell survival data presented in Figure 2
show that two distinct groups of cell lines can be distinguished: TMZ
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Figure 2 Clonogenic cell survival after 24 h exposure of 16 cancer cell lines to temozolomide (TMZ). The results for AMC 3046, AMC 3344, VU-28,
VU-98, VU-109, VU-110 and VU-122 have already been published (van Nifterik et al, 2007). Error bars represent the mean±s.d. (n¼ 2).
Table 1 Primer and probe sequences, location and amplicon of MGMT gene promoter for the methylation-specific PCR (MSP), quantitative real-time
MSP (qMSP) and primer sequences of MGMT promoter for bisulphite-sequencing technique
Name Sequence (5030) y bp from TSS Amplicon (bp)
MSP1+qMSP MGMT primers Fw: GATTTTTATTAAGCGGGCGTC 476-456 109
Rv: CTTTTCCTATCACAAAAATAATCCG 392-368
qMSP MGMT probe JOE TCCTAAAAACGCGCGAAAATCGTAAAA BHQ1 453-428
MSP2 MGMT primers (Esteller et al, 1999) Fw: TTTCGACGTTCGTAGGTTTTCGC 51-73 81
Rv: GCACTCTTCCGAAAACGAAACG 110-131
Bisulphite-sequence primers Fw: GGTAAATTAAGGTATAGAGTTTTAGG 354-329 464
Rv: ACCCAAACACTCACCAAAT 91-109
Abbreviations: TSS¼ transcription start site; bp¼ base pairs; Fw¼ forward primer; Rv¼ reverse primer.
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sensitive and TMZ resistant. The two separate groups can also be
shown by ascertaining the surviving fraction (SF) of the cell lines
after exposure to 250mM TMZ, as depicted in Table 2. Cell lines
that did not survive this treatment (SF¼ 0) were defined as
sensitive for TMZ, whereas cell lines showing at least an SF of 0.4
were considered TMZ resistant.
MGMT protein expression
Sixteen cell lines were tested for expression of the MGMT protein
by western blot analysis to investigate its ability to predict cell
survival after TMZ exposure. As shown in Figure 3A, eight cell
lines exhibit expression of the MGMT protein, including four GBM
(AMC 3344, VU-28, VU-110 and T98) and four other carcinomas
(A-431, HT-29, PC-3 and SW1573). The levels of expression ranged
from high (HT-29) to (very) low (AMC 3344). The other eight cell
lines (7 GBM and 1 astrocytoma grade III) did not express
detectable levels of the MGMT protein. The MGMT protein was
detected in all TMZ-resistant cell lines, whereas no MGMT protein
could be detected in cell lines that were TMZ sensitive.
Methylation analysis
To determine the methylation status of the promoter of the MGMT
gene, several techniques were used: MS-MLPA (semi-quantitative),
MSP, qMSP (quantitative) and bisulphite sequencing.
MGMT promoter methylation analysis by MS-MLPA The pro-
moter methylation levels in all 16 cell lines as determined by
MS-MLPA were obtained using three probes (directed against
different CpGs in the MGMT promoter). The mean results of two
independent experiments are shown in Table 2. Most regions with
low methylation levels (0–40%) were found in the group of cell
lines that were resistant to TMZ. However, low methylation levels
were also found for probe B in the TMZ-sensitive cell lines VU-98
and VU-122. In contrast, high methylation levels (75–100%) were
found mainly in the group of cell lines that were sensitive for TMZ.
However, high methylation levels were also found for probe A in
the TMZ-resistant cell lines HT-29, SW 1573 and T98. The areas
with intermediate methylation levels (40–75%) appeared in both
TMZ sensitive and resistant cell lines. A limited association
between TMZ sensitivity and MGMT promoter methylation was
found (Table 2). Presence of at least 2 out of 3 low (0–40%)
methylated CpGs determined resistance to TMZ in 5 out of 8 cell
lines (63%). Cell lines sensitive to TMZ could only be predicted
when at least 2 out of 3 CpGs were highly (75–100%) methylated.
This was the case in 4 out of 8 cell lines (50%). For none of the in-
between results (i.e. all other combinations of low, intermediate,
and high methylated CpGs) was a match found with sensitivity for
TMZ in 7 out of 16 cell lines (44%). Overall, MS-MLPA was
predictive for TMZ sensitivity in 9 out of 16 cell lines (56%).
MGMT promoter methylation analysis by MSP Two different
primer sets for different locations within the MGMT promoter
were used to determine the methylation status by MSP. The MSP1
covers the MS-MLPA probe A and MSP2 covers MS-MLPA probe C
(see Figure 1). The results for the primer sets MSP1 and MSP2
(Table 2; Figure 3B) showed methylation positivity for all but two
cell lines. Although most cell lines tested positive, there was a clear
difference in intensity of PCR products detected. Apparently, the
MSP assays are very sensitive, thus necessitating a quantitative
assay to allow a better discrimination between the levels of MGMT
methylation.
MGMT promoter methylation analysis by qMSP The qMSP probe
was designed for the MSP1 region to gain insight into the relative
methylation levels in this region of the promoter of the MGMT
gene. The methylation levels as determined by qMSP are presented
as ratios, which indicate the relative amount of methylated MGMT
(as compared with ACTB). The results are shown in Table 2. The
ratios for the TMZ-resistant group range from 10.49 to 1338.38,
whereas the ratios for the TMZ-sensitive group range from 244.83
to 1460.92. All eight cell lines sensitive to TMZ showed methylation
(4200). The four GBM cell lines that were resistant to TMZ
Table 2 Temozolomide (TMZ) sensitivity (SF after 250 mM TMZ), MGMT promoter methylation status assessed by methylation-specific PCR (MSP),
methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), quantitative real-time MSP (qMSP) and western blot (WB) results for a
panel of cancer cell lines
WB
MS-MLPA (% methylation±s.d.) MSP (level of methylation)
qMSP
Cell line
250lM TMZ
(SF±s.d.)
MGMT
expression MS-MLPA A MS-MLPA B MS-MLPA C MSP1 MSP2
Ratio
(mMGMT/
ACTB) 1000
A431 0.55±0.02 y 66.5±1.5 63.5±2.5 64±1 ++ ++ 607.23
HT-29 0.97±0.01 y 94±0 0 0 ++  1169.76
PC3 0.75±0 y 0 0 0  + 42.90
SW1573 0.44±0.06 y 100±0 73±5 0 ++ ++ 1338.38
AMC 3344 0.39±0.01 y 12.5±12,5 0 58±1 + + 31.32
VU-28 1.08±0.26 y 0 0 0 + + 170.16
VU-110 0.93±0.01 y 0 0 0   0
T98 0.74 y 99±1 58.5±1.5 55.5±5.5 ++ + 901.86
AMC 3046 0 n 62±0 59±1 62±1 + + 510.35
D384 0 n 83±1 82±6 92.5±1.5 ++ ++ 1460.92
Gli6 0 n 48±2 42.5±2.5 63.5±5.5 ++ ++ 245.08
Hs 683 0 n 97±3 93±4 98±2 ++ ++ 502.59
U251 0 n 77.5±14,5 66±2 100±0 ++ ++ 1243.66
VU-98 0 n 51.5±0.5 30±2 97.5±2.5 + ++ 244.83
VU-109 0 n 97.5±2.5 43.5±4.5 100±0 + ++ 808.58
VU-122 0 n 45±3 0 41±6 + + 297.38
Abbreviations: SF¼ surviving fraction; s.d.¼ standard deviation; ¼ unmethylated; +¼methylated; ++¼ highly methylated; MGMT¼O6-methylguanine-DNA methyltransfer-
ase; mMGMT¼methylated MGMT promoter; ACTB¼ b-actin gene; MS-MLPA results: white¼ unmethylated, grey¼methylated, dark¼ highly methylated; y¼ yes; n¼ no.
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showed no or low methylation levels (o200), except for cell line
T98. For the four non-glioma cell lines, the opposite was found,
these cell lines showed high levels of methylation, except for cell
line PC-3 (1 out of 4 cell lines (25%)). Therefore, no association
was found between the qMSP data and the cytotoxic response of
the non-glioma cell lines to 250 mM TMZ. The TMZ-resistant GBM
cell lines (with the exception of T98) and the TMZ-sensitive glioma
cell lines showed a good relationship between qMSP data and the
cytotoxic response to TMZ (11 out of 12 cell lines (92%)).
The qMSP data also showed a good association with data from
MS-MLPA probe A.
MGMT promoter methylation analysis by bisulphite sequencing On
the basis of the results of earlier analyses (Table 2), six GBM cell
lines (three with and three without expression of the MGMT
protein) were analysed by bisulphite sequencing (in total 62 CpGs;
see Figure 1). A summary of the bisulphite sequence results is
shown in Figure 3C. All 62 CpGs were completely unmethylated in
cell line AMC 3344 and almost completely unmethylated in cell
lines VU-28 and VU-110. Unfortunately, we were not able to
interpret the results at the 30 end of the PCR product in these cell
lines. In the MGMT-negative cell lines D384, Hs 683 and U251, the
25 CpGs (2–26) located at the 50 end (313-153 bp from TSS)
were completely methylated or contained both methylated and
unmethylated CpGs. In addition, the 12 CpGs (51–62) located at
the 30 end were completely or almost completely methylated
(þ 29-þ 90 bp from TSS). Methylation levels in these two CpG
locations seem to correlate well with TMZ sensitivity. No or partial
methylation was detected at CpGs 27–50. The 50 and 30 region
cover the MS-MLPA probes B (CpG 2) and C (CpG 59) and
these bisulphite-sequencing results show an excellent relationship
with data from MS-MLPA probe B and MS-MLPA probe C.
Bisulphite sequencing predicted TMZ sensitivity in all six tested
cell lines (100%).
DISCUSSION
In this study, we determined the sensitivity to TMZ, assessed by
clonogenic cell survival, in a panel of human tumour cell lines,
mostly derived from GBM. Sensitivity of TMZ correlated with the
MGMT promoter methylation status (assessed by MS-MLPA, MSP,
qMSP and bisulphite sequencing) and MGMT protein expression
(western blot).
Methylation of the CpGs in the promoter region of the MGMT
gene can cause transcriptional silencing, resulting in an absent
gene product (i.e. the MGMT protein), which in turn is responsible
for failure of repair of the (TMZ-induced) O6-methylated guanine
lesions in the DNA. Transcriptional silencing of the MGMT gene
by promoter methylation has been shown in cell lines as well as in
human tumour tissues (Qian and Brent, 1997; Watts et al, 1997;
Esteller et al, 1999). The fact that in this study, the absence of the
protein indeed reflected cells that are sensitive to TMZ, as shown
in Figure 4, agrees with these earlier findings. It is worth noting
that expression of the MGMT protein showed a 100% positive
match with TMZ resistance, with undetectable levels of MGMT
protein in TMZ-sensitive cells and varying levels of MGMT protein
in TMZ-resistant cells.
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Figure 3 (A) Western blot analysis for the expression of O6-methylguanine-DNA methyltransferase (MGMT) on a panel of four carcinoma (A-431,
HT-29, PC-3 and SW1573) and 12 glioma cell lines. For all samples, 50 mg of total protein were tested, except for the cell line HT-29 (25 mg). The AMC
3344* was also analysed with 100 mg. (B) Methylation-specific PCR (MSP) results for the MGMT gene promoter using the primer sets MSP1, MSP2
en control (ACTB) for a selection of six cell lines. 1: CaSki (cervical cancer cell line/positive control), 2: unmodified DNA (negative control), 3: unmethylated
DNA (primary keratinocytes/negative control), 4: H2O, 5: AMC 3344, 6: VU-28, 7: VU-110, 8: D384, 9: HS683, 10: U251. (C) Summary of bisulphite
sequencing in six GBM cell lines (three with MGMT expression and three without). A total of 62 CpG dinucleotides (CpGs) within the promoter region of
MGMT were analysed and are represented as circles. Each row represents one individual cell line. Closed circles represent cytosine (methylated), open
circles represent uracil (unmethylated) and grey circles represent a peak with both cytosine and uracil.
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Similarly, Hermisson et al (2006) showed that MGMT activity
correlated with MGMT expression and clonogenic survival after
TMZ exposure in human glioma cells. Although Bobola et al (1996)
showed that MGMT is a determinant of resistance in medullo-
blastoma and glioma-derived cell lines, they found disparity in the
contribution of MGMT to TMZ sensitivity. They state that the lack
of correlation between the amount of MGMT expression and the
degree of sensitivity to TMZ, and the variability in cytotoxicity in
cell lines without MGMT indicate that other factors are involved in
resistance. This could also be the case in the cell lines tested in our
study, as we found disparities that were similar to those of Bobola
et al (1996). For instance, the mismatch repair system or p53 could
also be involved in resistance to TMZ in glioma cells.
This study shows that the detection of DNA methylation as a
predictor of TMZ response is highly dependent on the technique
used and the CpGs analysed. The probes of MS-MLPA had limited
predictability (56%). Using MSP in a conventional manner seemed
too sensitive, whereas conversion to a quantitative assay (qMSP)
enabled a better prediction for glioma cells (92%) based on levels
of methylation. Bisulphite-sequencing analysis predicted TMZ
sensitivity in all tested samples (100%) and confirmed that MGMT
methylation is heterogeneous, as even in the TMZ-resistant cell
lines, there are regions in the MGMT promoter that remain
unmethylated, that is from CpGs 27 to 50. Consequently, these
regions should be avoided when designing methylation assays for
clinical applications. Furthermore, bisulphite sequencing con-
firmed qMSP and part of the MS-MLPA results and showed two
important regions in the promoter of the MGMT gene that are of
interest for the relationship between MGMT promoter methylation
and silencing of theMGMT gene. First, the regions in the promoter
indicated by the primers and probe of the qMSP technique
(392-368 bp from TSS) extended with the location of CpGs 1
to 26 as analysed by bisulphite sequencing (328-153 bp from
TSS), including the CpGs from MS-MLPA probes A and B. The
second area is located upstream from the TSS covered by CpGs 51
to 62 as analysed by bisulphite sequencing and by the MSP2
primers, also including the CpG from MS-MLPA probe C (þ 29-
þ 131 bp from TSS). This information can be used to design new
primers and/or probes for MS-MLPA and/or qMSP.
In the literature, a limited amount of CpGs is usually tested for
determination of the methylation status. The MSP primer set used in
this study (MSP2) has been used in other studies (Esteller et al,
1999, 2000; Brell et al, 2005; Jeuken et al, 2007; Rodriguez et al, 2008;
Yachi et al, 2008). Primer sets that are also often used are located
close to or in the same area as MSP2 (Hegi et al, 2005;
Vlassenbroeck et al, 2008; Dunn et al, 2009; Sadones et al, 2009).
Although this seems to be a good location for analysis of
methylation patterns, perhaps other and/or more combinations of
methylated CpGs would be better predictors of blocking transcrip-
tion of theMGMT gene, hence silencing the gene, which may predict
TMZ sensitivity. For instance, the area farther downstream of the
TSS (392-153 bp from TSS) may also prove to be of interest.
Studies with human glioma tumour samples often revealed a
lack of correlation between MGMT protein expression and MGMT
promoter methylation status (Brell et al, 2005; Jeuken et al, 2007;
Preusser et al, 2008; Rodriguez et al, 2008; Yachi et al, 2008).
Nevertheless, patient studies that investigated the relationship
between either MGMT protein expression or MGMT promoter
methylation and survival of patients with a GBM who had received
TMZ as adjuvant chemotherapy have shown promising results. For
instance, two studies showed a (negative) correlation between
MGMT protein expression and patient survival (Chinot et al, 2007;
Nagane et al, 2007). Other studies found that MGMT promoter
methylation correlated with patient survival (Hegi et al, 2005;
Dunn et al, 2009; Sadones et al, 2009).
Often no correlation is found between promoter methylation and
protein expression and both can have prognostic significance in
relation to survival of patients treated with TMZ for GBM. Possible
explanations may be found in imperfections of the experiment design
and/or techniques used. In case of promoter methylation analysis, the
promoter region chosen to be investigated may be of influence on the
outcome, as described before. In this respect, the technique of
MS-MLPA is, despite all its advantages, limited as it can only
determine the methylation status of CpGs that are situated within an
HhaI restriction site. Furthermore, MSP analysis results may fail in a
significant amount of the samples (Hegi et al, 2005; Rodriguez et al,
2008). Another aspect of many techniques is that differences in
MGMT status between individual cells cannot be detected, even
though several studies have shown the intratumoural heterogeneity of
human gliomas for MGMT protein expression (Citron et al, 1991;
Belanich et al, 1996). Moreover, discrimination between tumour and
non-tumour cells in clinical tumour samples is not possible with
many of the techniques used and the outcome may be distorted by
contamination with non-tumour cells. Techniques such as MSP,
qMSP, bisulphite sequencing and WB cannot discriminate. In vitro
studies, as the present one, do not have this complication, as tumour
cell lines are pure neoplastic cell populations. In this respect,
immunohistochemistry, determining the expression of the MGMT
protein per individual cell, may be a better technique for screening
human tumour samples. Nevertheless, immunohistochemistry also
has disadvantages, as reported in several studies (Jeuken et al, 2007;
Capper et al, 2008; Preusser et al, 2008; Rodriguez et al, 2008). Among
others, problems were reported with interobserver variability and
interpretation of MGMT expressing non-neoplastic infiltrating cells.
In addition, suitable techniques such as bisulphite sequencing are
often too complex, time consuming and expensive for routine
application on tumour samples. On the other hand, techniques such
as MSP or immunohistochemistry are easy-to-use and cost-efficient,
but have other disadvantages.
In conclusion, MGMT protein expression more than the level of
MGMT promoter methylation predicts the response to TMZ in
human tumour cell lines. Future research should focus on gaining
more knowledge of methylation patterns in the promoter region
and their relationship with protein expression. In this respect,
choosing the appropriate assay that will be accurate, reliable and
convenient enough will be of great importance for application in
the clinical setting.
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